KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVS) EBT (2016 - 2025)

Novartis Ag's EBT history spans 14 years, with the latest figure at $4.5 billion for Q2 2025.

  • On a quarterly basis, EBT rose 17.96% to $4.5 billion in Q2 2025 year-over-year; TTM through Jun 2025 was $20.5 billion, a 43.96% increase, with the full-year FY2025 number at $16.4 billion, up 19.88% from a year prior.
  • EBT hit $4.5 billion in Q2 2025 for Novartis Ag, down from $7.0 billion in the prior quarter.
  • Over the last five years, EBT for NVS hit a ceiling of $7.0 billion in Q4 2024 and a floor of $514.0 million in Q1 2021.
  • Historically, EBT has averaged $3.6 billion across 5 years, with a median of $4.6 billion in 2022.
  • Biggest five-year swings in EBT: skyrocketed 164.95% in 2021 and later crashed 30.28% in 2024.
  • Tracing NVS's EBT over 5 years: stood at $6.0 billion in 2021, then fell by 20.9% to $4.7 billion in 2022, then grew by 10.25% to $5.2 billion in 2023, then soared by 34.19% to $7.0 billion in 2024, then tumbled by 34.99% to $4.5 billion in 2025.
  • Business Quant data shows EBT for NVS at $4.5 billion in Q2 2025, $7.0 billion in Q4 2024, and $3.8 billion in Q2 2024.